Phase II Study of Venetoclax Added to Cladribine Plus Low Dose Cytarabine (LDAC) Induction Followed by Consolidation With Cladribine Plus LDAC Alternating With 5-Azacitidine in Patients With Untreated AML
Phase of Trial: Phase II
Latest Information Update: 20 Nov 2018
At a glance
- Drugs Azacitidine (Primary) ; Azacitidine (Primary) ; Cladribine (Primary) ; Cytarabine (Primary) ; Venetoclax (Primary)
- Indications Acute myeloid leukaemia
- Focus Therapeutic Use
- 06 Nov 2018 Planned End Date changed from 31 Jan 2020 to 3 Jan 2020.
- 06 Nov 2018 Planned primary completion date changed from 31 Jan 2020 to 3 Jan 2020.
- 25 Oct 2018 Planned End Date changed from 31 Jan 2021 to 31 Jan 2020.